ES2724989T3 - Derivados 5-[(piperazin-1-il)-3-oxopropil]imidazolidin-2,4-diona como inhibidores de ADAMTS para el tratamiento de la osteoartritis - Google Patents
Derivados 5-[(piperazin-1-il)-3-oxopropil]imidazolidin-2,4-diona como inhibidores de ADAMTS para el tratamiento de la osteoartritis Download PDFInfo
- Publication number
- ES2724989T3 ES2724989T3 ES15813831T ES15813831T ES2724989T3 ES 2724989 T3 ES2724989 T3 ES 2724989T3 ES 15813831 T ES15813831 T ES 15813831T ES 15813831 T ES15813831 T ES 15813831T ES 2724989 T3 ES2724989 T3 ES 2724989T3
- Authority
- ES
- Spain
- Prior art keywords
- oxopropyl
- dione
- imidazolidin
- methyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN[C@]1C(*)(C2)C2CCCC1 Chemical compound CN[C@]1C(*)(C2)C2CCCC1 0.000 description 23
- LZEJDLSNEQZCDI-UHFFFAOYSA-N CC(C(N(CC1)CCN1c1cccc(Cl)c1C)=O)=C Chemical compound CC(C(N(CC1)CCN1c1cccc(Cl)c1C)=O)=C LZEJDLSNEQZCDI-UHFFFAOYSA-N 0.000 description 1
- SIBYATXVKTVORH-MDYZWHIJSA-N CC(C)[n]1ncc(-c2cc(N(CC3)[C@@H](C)CN3C(CCC(C3CC3)(C(N3)=O)NC3=O)=O)ccc2)c1 Chemical compound CC(C)[n]1ncc(-c2cc(N(CC3)[C@@H](C)CN3C(CCC(C3CC3)(C(N3)=O)NC3=O)=O)ccc2)c1 SIBYATXVKTVORH-MDYZWHIJSA-N 0.000 description 1
- VYARDCSUIVAJSF-FNORWQNLSA-N CC(C/C=C(\C)/N)(C=C)F Chemical compound CC(C/C=C(\C)/N)(C=C)F VYARDCSUIVAJSF-FNORWQNLSA-N 0.000 description 1
- XKSOCXXAXUMGQC-JMTKMGNOSA-N C[C@@H](CN(CC1)C(CCC(C2CC2)(C(N2)=O)NC2=O)=O)N1c1cccc(-c2c(C)[o]nc2C)c1 Chemical compound C[C@@H](CN(CC1)C(CCC(C2CC2)(C(N2)=O)NC2=O)=O)N1c1cccc(-c2c(C)[o]nc2C)c1 XKSOCXXAXUMGQC-JMTKMGNOSA-N 0.000 description 1
- DACNMHXVSICLIS-FXIRQEPWSA-N C[C@@H](CN(CC1)C(CCC(C2CC2)(C(N2)=O)NC2=O)=O)N1c1cccc(-c2ccn[n]2C)c1 Chemical compound C[C@@H](CN(CC1)C(CCC(C2CC2)(C(N2)=O)NC2=O)=O)N1c1cccc(-c2ccn[n]2C)c1 DACNMHXVSICLIS-FXIRQEPWSA-N 0.000 description 1
- XSWFFTOMNHATMS-UHFFFAOYSA-N Cc(c(N1CCNCC1)ccc1)c1Cl Chemical compound Cc(c(N1CCNCC1)ccc1)c1Cl XSWFFTOMNHATMS-UHFFFAOYSA-N 0.000 description 1
- ZQDVPHPJORQTOU-UHFFFAOYSA-N NC(CCC(c(cc1)ccc1F)=O)=O Chemical compound NC(CCC(c(cc1)ccc1F)=O)=O ZQDVPHPJORQTOU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14307129 | 2014-12-22 | ||
| PCT/EP2015/080430 WO2016102347A1 (en) | 2014-12-22 | 2015-12-18 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2724989T3 true ES2724989T3 (es) | 2019-09-18 |
Family
ID=52345014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15813831T Active ES2724989T3 (es) | 2014-12-22 | 2015-12-18 | Derivados 5-[(piperazin-1-il)-3-oxopropil]imidazolidin-2,4-diona como inhibidores de ADAMTS para el tratamiento de la osteoartritis |
Country Status (50)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3501B1 (ar) | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
| GB201610056D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| GB201610055D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| CN107540648A (zh) * | 2017-08-09 | 2018-01-05 | 江苏工程职业技术学院 | 一种达格列净的制备方法 |
| CN107652277A (zh) * | 2017-08-09 | 2018-02-02 | 江苏工程职业技术学院 | 一种依帕列净的制备方法 |
| WO2021011723A1 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis hydantoin compounds and related compositions and methods |
| JP2023513121A (ja) * | 2020-02-04 | 2023-03-30 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Ａｄａｍｔｓ阻害剤、その製造および医薬用途 |
| WO2021204185A1 (zh) * | 2020-04-10 | 2021-10-14 | 深圳信立泰药业股份有限公司 | 一种苯并[d]氮杂卓类衍生物蛋白聚糖酶2抑制剂及其制备方法和医药用途 |
| CN113735825B (zh) * | 2020-05-27 | 2024-08-27 | 成都康弘药业集团股份有限公司 | 1,2,3,6-四氢吡啶类化合物及其制备方法和用途 |
| CN113754635B (zh) * | 2020-06-02 | 2024-06-21 | 成都康弘药业集团股份有限公司 | 稠环类化合物及其制备方法和用途 |
| WO2022007866A1 (zh) * | 2020-07-09 | 2022-01-13 | 深圳信立泰药业股份有限公司 | 并三环类衍生物、其制备方法及其在医药上的应用 |
| CN113943255B (zh) * | 2020-07-17 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法 |
| CN116723840A (zh) * | 2020-12-15 | 2023-09-08 | 加拉帕戈斯股份有限公司 | (5s)-环丙基-5-[3-[(3s)-4-(3,5-二氟苯基)-3-甲基-哌嗪-1-基]-3-氧代-丙基]咪唑烷-2,4-二酮的固体形式 |
| AU2021399788A1 (en) | 2020-12-15 | 2023-08-03 | Lakefront Biotherapeutics Nv | Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione |
| WO2022212638A1 (en) * | 2021-04-02 | 2022-10-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Prodrugs of adamts inhibitors, preparation methods and medicinal uses thereof |
| TW202321221A (zh) * | 2021-08-03 | 2023-06-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 抑制adamts-5和/或adamts-4功能的化合物的晶型及其製備方法和應用 |
| KR20240140825A (ko) | 2023-03-17 | 2024-09-24 | 주식회사 셀러스 | 이미다졸리딘 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556670A (en) * | 1982-12-06 | 1985-12-03 | Pfizer Inc. | Spiro-3-hetero-azolones for treatment of diabetic complications |
| HU198212B (en) * | 1984-07-20 | 1989-08-28 | Pfizer | Process for production of spiro-imidasolones |
| US5043447A (en) * | 1987-04-24 | 1991-08-27 | Syntex Pharmaceuticals, Ltd. | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
| GB0405101D0 (en) | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| ES2588484T3 (es) | 2012-04-13 | 2016-11-03 | Rottapharm Biotech S.R.L. | Anticuerpo anti-ADAMTS-5, derivados y usos del mismo |
| AR092971A1 (es) * | 2012-10-26 | 2015-05-06 | Lilly Co Eli | Inhibidores de agrecanasa |
| EP2953932B1 (en) | 2013-02-06 | 2017-03-01 | Merck Patent GmbH | Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis |
| JO3501B1 (ar) | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
-
2015
- 2015-11-19 JO JOP/2015/0284A patent/JO3501B1/ar active
- 2015-12-14 TW TW104141953A patent/TWI687414B/zh active
- 2015-12-18 MX MX2017008048A patent/MX2017008048A/es active IP Right Grant
- 2015-12-18 EA EA201791451A patent/EA030637B1/ru unknown
- 2015-12-18 RU RU2017126187A patent/RU2693459C2/ru active
- 2015-12-18 MD MDE20170225T patent/MD3237406T2/ro unknown
- 2015-12-18 CN CN201580070274.0A patent/CN107108579B/zh active Active
- 2015-12-18 NZ NZ732909A patent/NZ732909A/en unknown
- 2015-12-18 WO PCT/EP2015/080430 patent/WO2016102347A1/en not_active Ceased
- 2015-12-18 JP JP2017551003A patent/JP6636539B2/ja active Active
- 2015-12-18 ES ES15813831T patent/ES2724989T3/es active Active
- 2015-12-18 EP EP15813831.3A patent/EP3237406B1/en active Active
- 2015-12-18 PL PL15813831T patent/PL3237406T3/pl unknown
- 2015-12-18 DK DK15813831.3T patent/DK3237406T3/da active
- 2015-12-18 HK HK18105455.7A patent/HK1245793B/en unknown
- 2015-12-18 EP EP19154886.6A patent/EP3575294A1/en not_active Withdrawn
- 2015-12-18 SI SI201530668T patent/SI3237406T1/sl unknown
- 2015-12-18 MY MYPI2017702301A patent/MY189764A/en unknown
- 2015-12-18 CA CA2971110A patent/CA2971110C/en active Active
- 2015-12-18 ME MEP-2019-92A patent/ME03374B/me unknown
- 2015-12-18 BR BR112017013258-3A patent/BR112017013258B1/pt active IP Right Grant
- 2015-12-18 GE GEAP201514546A patent/GEP20197043B/en unknown
- 2015-12-18 KR KR1020177020379A patent/KR102711990B1/ko active Active
- 2015-12-18 TR TR2019/04158T patent/TR201904158T4/tr unknown
- 2015-12-18 UA UAA201707702A patent/UA122065C2/uk unknown
- 2015-12-18 RS RS20190497A patent/RS58617B1/sr unknown
- 2015-12-18 CU CUP2017000085A patent/CU20170085A7/xx unknown
- 2015-12-18 CR CR20170248A patent/CR20170248A/es unknown
- 2015-12-18 LT LTEP15813831.3T patent/LT3237406T/lt unknown
- 2015-12-18 SG SG11201705030SA patent/SG11201705030SA/en unknown
- 2015-12-18 AR ARP150104189A patent/AR103170A1/es active IP Right Grant
- 2015-12-18 TN TN2017000213A patent/TN2017000213A1/en unknown
- 2015-12-18 PE PE2017001122A patent/PE20171099A1/es unknown
- 2015-12-18 GE GEAP201914546A patent/GEAP201914546A/en unknown
- 2015-12-18 HU HUE15813831A patent/HUE042840T2/hu unknown
- 2015-12-18 HR HRP20190514TT patent/HRP20190514T1/hr unknown
- 2015-12-18 US US15/538,393 patent/US9926281B2/en active Active
- 2015-12-18 AU AU2015371400A patent/AU2015371400B2/en active Active
- 2015-12-18 MA MA41238A patent/MA41238B1/fr unknown
- 2015-12-18 PT PT15813831T patent/PT3237406T/pt unknown
- 2015-12-22 UY UY0001036470A patent/UY36470A/es not_active Application Discontinuation
-
2017
- 2017-05-24 GT GT201700107A patent/GT201700107A/es unknown
- 2017-06-07 ZA ZA2017/03905A patent/ZA201703905B/en unknown
- 2017-06-14 DO DO2017000139A patent/DOP2017000139A/es unknown
- 2017-06-15 SA SA517381743A patent/SA517381743B1/ar unknown
- 2017-06-18 IL IL252981A patent/IL252981B/en active IP Right Grant
- 2017-06-20 PH PH12017501160A patent/PH12017501160A1/en unknown
- 2017-06-21 NI NI201700081A patent/NI201700081A/es unknown
- 2017-06-21 CL CL2017001650A patent/CL2017001650A1/es unknown
- 2017-06-21 CO CONC2017/0006174A patent/CO2017006174A2/es unknown
- 2017-07-20 EC ECIEPI201746848A patent/ECSP17046848A/es unknown
-
2018
- 2018-02-14 US US15/896,779 patent/US10487060B2/en active Active
-
2019
- 2019-05-02 CY CY20191100464T patent/CY1121692T1/el unknown
- 2019-10-15 US US16/653,668 patent/US10941117B2/en active Active
- 2019-12-18 JP JP2019227801A patent/JP2020063278A/ja active Pending
-
2021
- 2021-01-05 US US17/141,902 patent/US11718588B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102711990B1 (ko) | 골관절염의 치료를 위한 에이디에이엠티에스 억제제로서 5-[(피페라진-1-일)-3-옥소-프로필]-이미다졸리딘-2,4-디온 유도체 | |
| HK1245793A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| KR102789883B1 (ko) | 안드로겐 수용체의 표적 분해용 화합물 및 방법 | |
| ES2485913T3 (es) | Compuestos novedosos útiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| US10550100B2 (en) | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | |
| KR20190101406A (ko) | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 | |
| WO2014014874A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
| EP3468955B1 (en) | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts 4 and 5 inhibitors for treating e.g. osteoarthritis | |
| SG191291A1 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| HK1241369A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы |